What Inpart does

Inpart is a cloud-based SaaS platform purpose-built for life sciences partnering, serving pharmaceutical, biotechnology, and academic organizations across the drug discovery and external innovation value chain. The platform comprises two core modules: Inpart Connect for asset and partner discovery across a global network, and Inpart Deal for end-to-end partnering CRM that centralizes interactions, evaluations, due diligence, and alliance management. A proprietary data engine harmonizes fragmented taxonomies and unstructured data into a standardized, AI-ready source of truth, hosted on ISO 27001 certified infrastructure in Geneva with synchronized Paris backup.

The company operates a subscription SaaS business model with annual terms, per-user licensing, and quote-based pricing for enterprise clients. Revenue is supplemented by optional professional services such as upgraded support and custom implementation. Inpart distributes primarily through direct enterprise field sales with a demo-driven motion, complemented by a self-service onboarding funnel at start.in-part.com. The company reports 500+ life sciences clients including 70% of the top 50 pharma, with 230+ universities and research institutes on the academic side, and references named enterprise customers such as Pfizer, Eli Lilly, Novartis, Novo Nordisk, AbbVie, and UCB.

Inpart is privately held and family-influenced, with co-founders Gilles Toulemonde (CEO) and David Carteret (CTO), and Caroline Toulemonde as COO. Legal entities span Inpart SA (France), IN-PART Publishing Ltd (UK), and Inova Inc. (US). The company owns the Labiotech.eu biotech media property, which functions as a content and lead-generation channel. No venture capital or private equity funding rounds have been disclosed, and revenue is not publicly reported.

Name

Inpart

Legal name

Inpart SA

Website

https://inpart.io

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

101–250 employees

Short description

Inpart is a cloud-based SaaS platform for life sciences partnering, serving 500+ pharmaceutical and biotech companies and 230+ academic institutions with partner discovery, deal management, and alliance tracking tools. It operates a per-user annual subscription model sold through enterprise field sales.

Ownership category

akta.pro rank

Product category

Biopharma Partnering Software

NAICS

Other Computer Related Services (541519), Computer Systems Design and Related Services (54151)

SIC

Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Data Management, Biostatistics & Statistical Programming FSP (HLAGAOAB)

akta.pro secondary industry

Market Access, Pricing & Reimbursement (Evidence Generation) FSP (HLAGAOAN)

Keywords

• Biopharma partnering platform
• Partner discovery software
• Alliance management system
• Asset sourcing platform
• Deal management CRM

Headquarters

HQ city

Lyon

HQ country

France

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

1. Platform Subscriptions: Inpart operates on a subscription SaaS model with annual subscription terms. Services are purchased per user with tiered pricing based on functionality (Connect and Deal products). Subscriptions auto-renew unless cancelled 60 days prior.
2. Professional Services: Additional professional services may be purchased including upgraded support and custom implementation assistance beyond standard platform onboarding.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Inpart provides a unified SaaS platform for life sciences R&D partnering, comprising two core products: Inpart Connect (partner and asset sourcing with global search across a network of science) and Inpart Deal (an end-to-end partnering CRM that centralizes interactions, evaluations, and agreements). The platform unifies data, insights, and workflows across scouting, search & evaluation, business development, due diligence, and alliance management for pharmaceutical, biotech, and academic institutions.

Product overview

Inpart offers a unified end-to-end platform for R&D partnerships comprising two core modules: Connect and Deal. Inpart Connect enables partner discovery and opportunity sourcing across a global network, while Inpart Deal serves as the partnering CRM for managing relationships, workflows, and agreements from initial contact through execution. The platform is built for life sciences organizations and supports solutions for Open Innovation, Research & Development, Search & Evaluation, Business Development, Due Diligence, and Alliance Management teams.

Differentiator

Problem solved

Functional benefit

Products and services

• Inpart Connect Partner discovery and opportunity sourcing module that enables users to uncover new partners and opportunities across a global network of science, conduct personalized landscaping, and access up-to-date information about assets available to license or acquire. Designed for life sciences business development and search & evaluation teams.
• Inpart Deal End-to-end partnering CRM that consolidates every interaction, email, and document in one place, tracks evaluation status, identifies roadblocks, generates reports, and manages the complete partnering lifecycle from contact through negotiation to signed agreements. Built for life sciences business development and alliance management.

Quantifiable outcome

• Cost savings of up to $4.8M annually
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• KoreaBIOcoreStrategic or Co-development PartnerKoreaBIO partnered with Inpart as an industry-leading biopharma partnering platform to support Korean biotech companies in connecting with global pharmaceutical partners and academic institutions.
• EvaluatecoreStrategic or Co-development PartnerInpart and Evaluate announced a strategic partnership to optimize biopharma dealmaking by combining Inpart's partnering platform capabilities with Evaluate's deal intelligence and analytics.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Veeva Systems: Veeva is the dominant life sciences cloud software provider offering Vault CDMS, CRM, and quality suites used by most large pharma companies. It competes with Inpart in the broader life sciences CRM and workflow space with deeper feature breadth, larger customer footprint, and significantly greater scale.
• Evaluate: Evaluate offers pharma market and deal intelligence, forecasting, and analytics to the same enterprise pharma audience. It is both a strategic partner and a competitor in deal intelligence workflows adjacent to Inpart's Deal module.
• Citeline (Pharma Intelligence): Citeline, the data and intelligence arm of Informa, provides Pharma Intelligence, Biomedtracker, and pipeline data services used by pharma R&D and BD teams. It is a broader incumbent whose pipeline intelligence overlaps with Inpart's search and evaluation workflows.
• Salesforce (Health Cloud): Salesforce Health Cloud and its AppExchange ecosystem serve pharma business development and medical affairs teams as a general-purpose CRM. It competes with Inpart Deal as a customizable but less-specialized alternative.
• Microsoft Cloud for Healthcare: Microsoft's healthcare cloud offering combines Dynamics 365, Teams, and Azure for pharma collaboration, CRM, and AI-enabled workflows. It competes as a broad incumbent platform with deep AI integration that could encroach on Inpart's AI-ready data vision.

Direct peers

• EBD Group (PartneringONE): EBD Group operates the PartneringONE platform that powers one-on-one partnering meetings at BIO Convention and other life sciences events. It is a direct competitor in life sciences business development partnering and asset sourcing, with the deepest industry event footprint.
• DealForma: DealForma provides biopharma deal intelligence and partnership analytics used by business development teams to benchmark transactions and evaluate opportunities. It overlaps directly with Inpart's search & evaluation and due diligence use cases for pharma BD teams.
• BIO (Biotechnology Innovation Organization): BIO runs the BIO Business Solutions and BIO One-on-One Partnering programs that connect biotech and pharma companies for licensing and partnership discussions. It overlaps with Inpart's university and biotech-to-pharma sourcing workflows at the industry-association level.

Emerging players

• BioCentury: BioCentury is a biopharma intelligence and partnering platform serving business development professionals with editorial, data, and BCIQ analytics. It competes in the same biopharma BD intelligence niche with a content-led go-to-market approach.

Others

• PitchBook: PitchBook provides private market deal intelligence used by pharma corporate development teams for M&A and investment scouting. It is adjacent rather than direct, serving the same buyer persona for external innovation and corporate development intelligence.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/inova_io
• LinkedInlinkedin.com/company/inpart-io

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inpart